91 results
8-K
EX-10.3
SLRX
Salarius Pharmaceuticals Inc
22 Feb 24
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
5:55pm
8-K
EX-10.2
SLRX
Salarius Pharmaceuticals Inc
22 Feb 24
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
5:55pm
8-K
EX-10.4
SLRX
Salarius Pharmaceuticals Inc
22 Feb 24
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
5:55pm
8-K
EX-10.1
SLRX
Salarius Pharmaceuticals Inc
22 Feb 24
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
5:55pm
8-K
EX-10.5
SLRX
Salarius Pharmaceuticals Inc
22 Feb 24
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
5:55pm
8-K
EX-10.1
98qnm t1x06w44cz35um
14 Jun 23
Departure of Directors or Certain Officers
6:47pm
8-K
EX-10.1
jr8sg fxgy7pgrwqlcs
16 May 23
Salarius Pharmaceuticals Announces $6 Million Private Placement
4:33pm
8-K
EX-10.2
9rpjyfa8szvwta
16 May 23
Salarius Pharmaceuticals Announces $6 Million Private Placement
4:33pm
8-K
EX-10.2
jc0 0q78c
22 Apr 22
Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering
8:47am
8-K
EX-10.1
tisyhzuy
22 Apr 22
Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering
8:47am
8-K
EX-10.1
kchybpfo
13 Jan 22
Salarius Pharmaceuticals Expands Oncology Pipeline Through Strategic Acquisition of Targeted Protein Degradation Portfolio from DeuteRx, LLC
4:05pm
8-K
EX-10.1
8wirq5
11 Dec 20
Entry into a Material Definitive Agreement
8:28am
8-K
EX-10.2
4x2ej13u dzk
19 Jun 20
Submission of Matters to a Vote of Security Holders
5:26pm
8-K
EX-10.1
5ugl49ks ker5yh
19 Jun 20
Submission of Matters to a Vote of Security Holders
5:26pm
8-K
EX-10.01
iagqrabukcu6b
29 Apr 20
Departure of Directors or Certain Officers
4:31pm
8-K
EX-10.1
hufq8djh
28 Oct 19
Salarius Pharmaceuticals and Aspire Capital Announce a $10.9M Common Stock Purchase Agreement
8:01am
8-K
EX-10.3
w9j62x74
16 Sep 19
Departure of Directors or Certain Officers
5:15pm
8-K
EX-10.5
hyuu 7jhvmkdhb2s99
16 Sep 19
Departure of Directors or Certain Officers
5:15pm